NCT00077779已完成3 期
A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Abbott
- 入组人数
- 854
- 试验地点
- 85
- 主要终点
- Clinical remission (CDAI<150).
研究概览
简要总结
The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Clinical remission (CDAI<150).
时间窗: 56 weeks
次要结局
未报告次要终点
研究者
研究点 (85)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative ColitisUlcerative ColitisNCT00385736Abbott576
已完成
2 期
A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's DiseaseCrohn's DiseaseNCT00445939Abbott90
已完成
3 期
Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's DiseaseCrohn's DiseaseNCT02499783AbbVie205
已完成
3 期
Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With MethotrexateRheumatoid ArthritisNCT00235859Abbott128
已完成
3 期
Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's DiseaseCrohn's DiseaseNCT02065570AbbVie514